CoChat

Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort

Open access
Willcocks, Rebecca J., Rooney, William D., Triplett, William T., Forbes, Sean C., Lott, Donovan J., Senesac, Claudia R., Daniels, Michael J., Wang, Dah‐Jyuu, Harrington, Ann T., Tennekoon, Gihan I., Russman, Barry S., Finanger, Erika L., Byrne, Barry J., Finkel, Richard S., Walter, Glenn A., Sweeney, H. Lee, Vandenborne, Krista · 2016 · Annals of Neurology
Cited by 161

The DOI matches its Crossref record.

Abstract

Objective: The aim of this study was to describe Duchenne muscular dystrophy (DMD) disease progression in the lower extremity muscles over 12 months using quantitative magnetic resonance (MR) biomarkers, collected across three sites in a large cohort. Methods: A total of 109 ambulatory boys with DMD (8.7 ± 2.0 years; range, 5.0–12.9) completed baseline and 1‐year follow‐up quantitative MR imaging (transverse relaxation time constant; MRI‐T 2 ), MR spectroscopy (fat fraction and 1 H 2 O T 2 ), and 6‐minute walk test (6MWT) measurements. A subset of boys completed additional measurements after 3 or 6 months. Results: MRI‐T 2 and fat fraction increased significantly over 12 months in all age groups, including in 5‐ to 6.9‐year‐old boys. Significant increases in vastus lateralis (VL) fat fraction were observed in 3 and 6 months. Even in boys whose 6MWT performance improved or remained stable over 1 year, significant increases in MRI‐T 2 and fat fraction were found. Of all the muscles examined, the VL and biceps femoris long head were the most responsive to disease progression in boys with DMD. Interpretation: MR biomarkers are responsive to disease progression in 5‐ to 12.9‐year‐old boys with DMD and able to detect subclinical disease progression in DMD, even within short (3–6 months) time periods. The measured sensitivity of MR biomarkers in this multicenter study may be critically important to future clinical trials, allowing for smaller sample sizes and/or shorter study windows in this fatal rare disease. Ann Neurol 2016;79:535–547

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.24599

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Willcocks, R. J., Rooney, W. D., Triplett, W. T., Forbes, S. C., Lott, D. J., Senesac, C. R., Daniels, M. J., Wang, D., Harrington, A. T., Tennekoon, G. I., Russman, B. S., Finanger, E. L., Byrne, B. J., Finkel, R. S., Walter, G. A., Sweeney, H. L., & Vandenborne, K.
Venue
Annals of Neurology
Publisher
Wiley
Published
2016-02-19
Volume
79
Issue
4
Pages
535-547
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2277280343
Cited by
161
References
0
FWCI
9.33
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.